{"prompt": "['Novartis', 'Confidential', 'Page 25', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'The risk to the patients in the study is that QVM149 is under development in asthma and', 'therefore it is possible that unexpected safety issues may be identified and the risk will be', 'minimized by compliance with the eligibility criteria and close clinical monitoring of patients.', 'The risks of side effects from the study medication are those known for the individual', 'components indacaterol acetate, glycopyrronium bromide and mometasone furoate. No', 'additional risks have been identified which might occur when the three components are', 'administered concurrently or from the same inhaler. Detailed risk-benefit information can be', \"obtained from the QVM149 Investigator's Brochure.\", 'Guidance to manage potential worsening of asthma symptoms will be provided to', 'investigators consistent with guideline recommendations (GINA 2017). Patients will receive', 'written instructions as to how to contact the investigator in the event of worsening of their', 'asthma symptoms. The investigator should discontinue study treatment for a given patient if,', \"on balance, he/she believes that continuation would be detrimental to the patient's well-being.\", 'Patients are also instructed that they can discontinue study treatment at any time, and for any', 'reason.', 'In summary, based on available data of components, it is anticipated that QVM149 150/50/80', 'g and QVM149 150/50/160 g will have a favorable benefit to risk profile in patients with', 'uncontrolled asthma.', '4 Population', 'The study population will consist of approximately 1251 male and female patients with', 'uncontrolled asthma aged 18 and above.', 'It is anticipated that approximately 2500 patients will need to be screened in order to', 'randomize approximately 1251 patients into the three treatment groups of the study with a', 'randomization ratio of 1:1:1, (i.e. approximately 417 patients in each of the treatment groups).', 'Drop-outs after randomization will not be replaced. This study will enroll multi-nationally and', 'patients will be stratified by previous ICS dose component of ICS/LABA therapy (medium or', 'high) and region.', '4.1 Inclusion criteria', '1. Written informed consent must be obtained before any study-related assessment is', 'performed. Only fully legally competent patients can be included (patients that are not', 'able to consent cannot be recruited in this trial).', '2. Male and female adult patient > 18 years old.', '3. Patients with a diagnosis of asthma for a period of at least 6 months prior to Visit 1 with', 'current asthma severity > step 4 (GINA 2017).', '4. Patients who have used ICS/LABA combinations for asthma for at least 3 months and at', 'stable medium or high dose of ICS/LABA for at least 1 month prior to Visit 1 (Appendix', '10).', '5. Patients must be symptomatic at screening despite treatment with medium or high stable', 'doses of ICS/LABA as defined by ACQ-7 score > 1.5 at visits 101 and 201', '(randomization visit).']['Novartis', 'Confidential', 'Page 26', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '6. Patients with history of at least one severe asthma exacerbation (Section 6.4.5) which', 'required medical care from a physician, ER visit (or local equivalent structure) or', 'hospitalization in the 12 months prior to Visit 1 and required systemic corticosteroid', '(SCS) treatment for at least 3 days including physician guided self-management treatment', 'with oral corticosteroids as part of written asthma action plan.', 'Previous severe asthma exacerbation in this context must be supported by', 'documentation (i.e. such as in source notes, pharmacy records, hospital records, or', 'chart records) of unplanned need for medical care at any primary care physician,', 'pulmonologist, emergency room and hospital due to an aggravation of asthma', 'symptoms and treatment with systemic corticosteroids due to severe asthma', 'exacerbation including physician guided self-management treatment with oral', 'corticosteroids as part of written asthma action plan.', '7. Pre-bronchodilator FEV1 of < 85 % of the predicted normal value for the', 'patient after withholding bronchodilators prior to spirometry (Table 5-2) at both Visit 101', 'and Visit 201.', 'Repeat testing is allowed once at each visit (by rescheduling the visit). Repeat of', 'Visit 101 should be scheduled on a date that would provide sufficient time to receive', 'confirmation from the spirometry central reviewer before randomization.', 'Re-screening is allowed once if patient fails to meet the criteria at the repeat visit.', '8.', 'Patients who demonstrate an increase in FEV1 of > 12% and 200 mL 15 to 30 minutes', 'after administration of 400 g salbutamol or 360 g albuterol (equivalent dose) through a', 'spacer device at Visit 101. Patients need to demonstrate reversibility at V101 by either a', 'positive reversibility test or with historical evidence of reversibility or positive bronchial', 'provocation test that was performed within 5 years prior to Visit 1 and according to', 'ATS/ERS guidelines. If reversibility is not demonstrated at Visit 101 the reversibility test', 'may be repeated once.', 'If reversibility is not demonstrated at Visit 101 (or after repeat) and historical evidence of', 'reversibility is not available (or was not performed according to the ATS/ERS guidelines)', 'the patients must be screen failed.', '4.2 Exclusion criteria', 'Patients fulfilling any of the following criteria are not eligible for inclusion in this study. No', 'additional exclusions may be applied by the investigator, in order to ensure that the study', 'population will be representative of all eligible patients.', '1. Patients who have a smoking history of greater than 20 pack years (Note: 1 pack is', 'equivalent to 20 cigarettes. 10 pack years = 1 pack /day X 10 yrs., or 1/2 pack/day X 20', 'yrs.).', '2. Patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).', '3. Patients who have had an asthma attack/exacerbation requiring systemic steroids or', 'hospitalization or emergency room visit within 6 weeks of Visit 1 (Screening). If patients', 'experience an asthma attack/exacerbation requiring systemic steroids or hospitalization or', 'emergency room visit between Visit 1 and Visit 201 they may be re-screened 6 weeks', 'after recovery from the exacerbation.']\n\n###\n\n", "completion": "END"}